iguratimod

Known as: N-[7-[(Methanesulfonyl)amino]-4-oxo-6-phenoxy-4H-1-benzopyran-3-yl]formamide 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Macrophage migration inhibitory factor (MIF) is a pleiotropic cytokine that has been implicated in a broad range of inflammatory… (More)
Is this relevant?
2015
2015
OBJECTIVE Iguratimod (IGU) is a new synthetic disease-modifying antirheumatic drug intended to treat patients with rheumatoid… (More)
Is this relevant?
2015
2015
Rheumatoid arthritis (RA) is a potentially destructive disease that may have a profound impact on patients’ function and quality… (More)
Is this relevant?
Review
2015
Review
2015
Iguratimod (IGU), a small-molecule compound, was developed as a disease-modifying antirheumatic drug in Japan. The… (More)
Is this relevant?
2015
2015
Iguratimod is a novel disease-modifying antirheumatic drug. A blue letter (safety advisory) for drug interaction between… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2013
2013
OBJECTIVES To investigate the efficacy and safety of iguratimod (T-614) in Japanese patients with active rheumatoid arthritis who… (More)
Is this relevant?
Review
2012
Review
2012
Iguratimod, a methanesulfonanilide, is a novel disease-modifying antirheumatic drug that has been developed exclusively in Japan… (More)
Is this relevant?
2009
2009
Iguratimod is a small molecule compound with anti-inflammatory and immunomodulatory actions, which has been developed as a… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
Is this relevant?
2007
2007
We conducted a 52-week clinical study of iguratimod in 394 Japanese patients with rheumatoid arthritis to evaluate the long-term… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2007
2007
We conducted a 28-week, randomized, double-blind, parallel-group study of iguratimod in 376 Japanese patients with active… (More)
Is this relevant?